Skip to main content
RHHBY logo

Roche Holding AG (RHHBY) Stock Price & Analysis

Roche Holding AG (RHHBY) — price $59.52 (-1.21%), as of the Nov 18, 2026 trading session; market cap $379B.

Educational signal · not a buy or sell recommendation · How to read this

$59.52 −$0.73 (-1.21%) Market Cap $379B

Roche Holding AG · RHHBY · Healthcare · Drug Manufacturers - General

Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors.

Price as of Nov 18, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • MRK · Merck & Co., Inc. · 69 /100
  • NVS · Novartis AG · 82 /100
  • ABBV · AbbVie Inc. · 83 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$59.52
Change on the day-1.21%
52-week range$47.05–$61.75
Market capitalisation$379B—
Price / earnings (trailing)26.45
Shares traded on the day110.0K
Beta (volatility vs the S&P 500)0.35

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $40, high $61, latest $60. $61 $40 high $61 Oct 17, 2025 Nov 18, 2026 · $60 $45Oct 17, 2025$40Oct 31, 2025$45Nov 14, 2025$48Nov 28, 2025$50Dec 12, 2025$53Dec 26, 2025$53Jan 9, 2026$55Jan 23, 2026$58Feb 6, 2026$59Feb 20, 2026$55Mar 6, 2026$47Mar 20, 2026$50Apr 2, 2026$51Apr 17, 2026$51May 1, 2026$51May 15, 2026$52May 29, 2026$52Jun 12, 2026$52Jun 26, 2026$52Jul 10, 2026$55Jul 24, 2026$57Aug 7, 2026$58Aug 21, 2026$55Sep 4, 2026$54Sep 18, 2026$52Oct 2, 2026$57Oct 16, 2026$61Oct 30, 2026$60Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Roche Holding AG (RHHBY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Weak
Debt/Equity Weak
ROE Strong
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Roche Holding AG (RHHBY), and what does it report?

Short answer · as of

Roche sells therapies across oncology, neuroscience, immunology and other disease areas, while its diagnostics operation supplies laboratory tests, instruments and reagents.

Research dated 2026-09-12.

Calling it merely a drug manufacturer misses a material part of the business: demand also comes from laboratories and healthcare systems running tests to detect or monitor disease.

2 · Latest results

What do the latest results show for Roche Holding AG (RHHBY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CHF 31.02B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CHF 31.02BCHF 7.02BCHF 1.09 (diluted)
Q4 FY2025CHF 30.32BCHF 5.42BCHF 0.84 (diluted)
Q2 FY2025CHF 15.92BCHF 3.71BCHF 0.58 (diluted)
Q4 FY2024CHF 31.64BCHF 2.02BCHF 0.32 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Roche Holding AG (RHHBY)?

Short answer · as of

The distress and quality screens read Altman Z 5.30 · Piotroski F 6. Trailing ratios: ROE 37.1% · ROA 12.6% · current ratio 1.23 · earnings yield 3.7% · free-cash-flow yield 5.2%.

4 · What to check next?

What should you watch next at Roche Holding AG (RHHBY)?

Short answer · as of

Current published price targets run low $63.00 · high $63.00 · consensus $63.00 · median $63.00 against a quoted price of $59.52 (as of Nov 18, 2026).

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is Roche Holding AG scored?

Roche combines medicine development with diagnostic testing under the same group. That makes its demand profile different from a pure pharmaceutical company or a stand-alone laboratory supplier: sales respond to clinical adoption of therapies as well as the use of tests, instruments and reagents across laboratory workflows.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
AstraZeneca PLC (AZNCF) Named competitor$189.90 Sep 25, 2026$294B— Model unavailable
Chugai Pharmaceutical Co., Ltd. (CHGCF) Named competitor$44.52 Nov 18, 2026$73.3B— Model unavailable
Daiichi Sankyo Company, Limited (DSKYF) Named competitor$17.72 Nov 18, 2026$32.3B— Model unavailable
Merck & Co., Inc. (MRK) Same industry, near in market value$137.78 Nov 18, 2026$340B— 5-pillar · not comparable
Novartis AG (NVS) Same industry, near in market value$155.21 Nov 18, 2026$293B— 5-pillar · not comparable
AbbVie Inc. (ABBV) Same industry, near in market value$286.01 Nov 18, 2026$506B— 5-pillar · not comparable
Amgen Inc. (AMGN) Same industry, near in market value$443.89 Nov 18, 2026$240B— 5-pillar · not comparable
Johnson & Johnson (JNJ) Same industry, near in market value$272.70 Nov 18, 2026$656B— 5-pillar · not comparable
Gilead Sciences, Inc. (GILD) Same industry, near in market value$170.26 Nov 17, 2026$211B— 5-pillar · not comparable
Pfizer Inc. (PFE) Same industry, near in market value$28.46 Nov 17, 2026$162B— 5-pillar · not comparable
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$59.56 Nov 18, 2026$122B— 5-pillar · not comparable
Eli Lilly and Company (LLY) Same industry, near in market value$1382.75 Nov 18, 2026$1.23T— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$63.00 – $63.00
Consensus target
$63.00
Median target
$63.00

Consensus record · Captured .

Measured against a quoted price of $59.52 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RHHBY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RHHBY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Roche Holding AG (RHHBY)?

Read these with our analysis →

Roche Holding AG Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

Why is Roche more than a pharmaceutical manufacturer?

Its pharmaceutical portfolio sits alongside a diagnostics business selling laboratory tests, instruments and reagents. Roche therefore participates in treatment decisions and in the testing used to identify and monitor disease.

What does Roche Diagnostics sell besides laboratory tests?

Roche Diagnostics also supplies instruments and reagents used by laboratories. Demand is therefore tied not only to test availability but also to testing activity across supported disease areas.

What is the RHHBY stock price today?

The last price recorded for Roche Holding AG (RHHBY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the RHHBY price target?

The analyst consensus price target for Roche Holding AG (RHHBY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 21 figures on this page — 17 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • 1. What is Roche Holding AG (RHHBY), and what does it report?: Sector / industry (provider taxonomy); Business description
  • 5. How is Roche Holding AG scored?: Business description; Sector / industry (provider taxonomy)
  • FAQ: Why is Roche more than a pharmaceutical manufacturer?: Business description; Sector / industry (provider taxonomy)
  • FAQ: What does Roche Diagnostics sell besides laboratory tests?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold RHHBY

Funds in our ETF coverage that list RHHBY among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
GMO International Quality ETF (QLTI)4.08%